AVITA Medical

AVITA Medical Equity

The The Equity of AVITA Medical (RCEL) as of Nov 11, 2026 is 4.50 M USD. In the previous year, The Equity was 49.06 M USD — a change of -90.83% (lower).

Equity

4.50 MUSD

YoY

-90.83%

Last updated:

In 2024, AVITA Medical's equity was 4.50 M USD, a -90.83% increase from the 49.06 M USD equity in the previous year.

The AVITA Medical Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2019
72.40 M USD
Jan 1, 2020
115.70 M USD
Jan 1, 2021
104.60 M USD
Jan 1, 2022
84.70 M USD
Jan 1, 2023
49.06 M USD
Jan 1, 2024
4.50 M USD
The AVITA Medical Equity history
YEAREquityYoY
4.50 MUSD-90.83%
49.06 MUSD-42.08%
84.70 MUSD-19.02%
104.60 MUSD-9.59%
115.70 MUSD+59.81%
72.40 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AVITA Medical Stock analysis

What does AVITA Medical do? AVITA Medical Inc is a company in the field of regenerative medicine that focuses on the development and marketing of innovative therapy products for the treatment of burns, chronic wounds, and skin defects. The company was founded in 1998 and is headquartered in Valencia, California. AVITA Medical Inc began with research in the field of regenerative medicine at the University of Western Australia, where the company developed its patented technology known as ReNovaCell. This technology allows for the extraction and cultivation of cells from a small area of skin to create a solution that contains the patient's own skin tissue on a large scale. AVITA Medical Inc's business model is based on the development and marketing of regenerative therapy products based on ReNovaCell technology. The company focuses on commercializing products that enable fast, safe, and effective treatment of burns, chronic wounds, and skin defects. AVITA Medical Inc operates in two main segments: regenerative medicine and aesthetic medicine. In regenerative medicine, the company offers a wide range of products based on ReNovaCell technology, including ReCell, a unique autologous cell therapy for rapid burn treatment, Kelo-Cote, a silicone gel formulation for scar treatment, and therapy-complementary wound treatments. In aesthetic medicine, the company distributes a variety of products under the brand RestoreSkin, which focuses on improving skin health and aesthetic appearance, including pore refinement, pigment reduction, and wrinkle reduction. AVITA Medical Inc has established itself as a leading provider of regenerative therapy products. The company has a strong presence both in the US and internationally and is actively advocating for the advancement of regenerative medicine. By developing innovative products that enable fast and effective treatment of skin defects, AVITA Medical Inc will continue to be a key player in regenerative medicine in the future. AVITA Medical is one of the most popular companies on Eulerpool.

Equity Details

Analyzing AVITA Medical's Equity

AVITA Medical's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding AVITA Medical's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating AVITA Medical's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

AVITA Medical's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in AVITA Medical’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about AVITA Medical stock

The Equity of AVITA Medical is 4.50 M USD in 2024.

The Equity of AVITA Medical changed from 49.06 M USD to 4.50 M USD, representing a -90.83% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity AVITA Medical since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's AVITA Medical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — AVITA Medical

All Key Metrics — AVITA Medical